Canada · Delayed Price · Currency is CAD Vaxil Bio Statistics
Total Valuation
Vaxil Bio has a market cap or net worth of CAD 438,242. The enterprise value is -25,758.
| Market Cap | 438,242 |
| Enterprise Value | -25,758 |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxil Bio has 3.98 million shares outstanding. The number of shares has increased by 26.20% in one year.
| Current Share Class | 3.98M |
| Shares Outstanding | 3.98M |
| Shares Change (YoY) | +26.20% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.61% |
| Owned by Institutions (%) | n/a |
| Float | 3.76M |
Valuation Ratios
The trailing PE ratio is 1.00.
| PE Ratio | 1.00 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.97, with zero debt.
| Current Ratio | 17.97 |
| Quick Ratio | 17.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 39.89% and return on invested capital (ROIC) is -16.91%.
| Return on Equity (ROE) | 39.89% |
| Return on Assets (ROA) | -16.59% |
| Return on Invested Capital (ROIC) | -16.91% |
| Return on Capital Employed (ROCE) | -21.36% |
| Weighted Average Cost of Capital (WACC) | 3.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.29% in the last 52 weeks. The beta is -0.19, so Vaxil Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.19 |
| 52-Week Price Change | -35.29% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.32 |
| Relative Strength Index (RSI) | 30.88 |
| Average Volume (20 Days) | 4,428 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -255,000 |
| Pretax Income | 376,000 |
| Net Income | 379,000 |
| EBITDA | n/a |
| EBIT | -255,000 |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
The company has 464,000 in cash and no debt, with a net cash position of 464,000 or 0.12 per share.
| Cash & Cash Equivalents | 464,000 |
| Total Debt | n/a |
| Net Cash | 464,000 |
| Net Cash Per Share | 0.12 |
| Equity (Book Value) | 1.19M |
| Book Value Per Share | 0.30 |
| Working Capital | 509,000 |
Cash Flow
| Operating Cash Flow | -276,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -276,000 |
| FCF Per Share | -0.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaxil Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.20% |
| Shareholder Yield | -26.20% |
| Earnings Yield | 99.65% |
| FCF Yield | -62.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on May 15, 2025. It was a reverse split with a ratio of 0.02.
| Last Split Date | May 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |